A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
Mental Health & Behavioral Research
What is the purpose of this trial?
This study will test whether CVL-562 (PF-06412562), a dopamine 1 partial agonist novel compound, affects working memory neural circuits in patients with early episode schizophrenia. The overall aim is to establish neuroimaging biomarkers of the Dopamine Receptor 1/Dopamine Receptor 5 Family (D1R/D5R) target engagement to accelerate development of D1R/D5R agonists in humans to treat cognitive impairments that underlie functional disability in schizophrenia, a key unaddressed clinical and public health concern.
- Ages18 years - 45 years
- Trial withNational Institute of Mental Health/NIH/DHHS
- Start Date11/10/2020
- End Date12/31/2023
- Last Updated12/22/2022
- Study HIC#2000027506